Key Takeaways
- •A single high dose of 25 mg psilocybin produced lasting changes in brain function and structure, according to researchers at UC San Francisco.
- •Scientists recruited 28 healthy adults with no prior psychedelic experience for a placebo-controlled trial.
- •Researchers used EEG to track brain activity during sessions.
A single high dose of 25 mg psilocybin produced lasting changes in brain function and structure, according to researchers at UC San Francisco. Participants experienced shifts that improved their mental well-being for weeks. The study appeared in Nature Communications.
Study Methods and Participants
Scientists recruited 28 healthy adults with no prior psychedelic experience for a placebo-controlled trial. They gave participants two doses one month apart: a low 1 mg dose as control, followed by 25 mg. Sessions occurred in a dimly lit, aesthetically pleasing setting where people wore eye masks, lay on a bed, listened to music, and received monitoring.
Researchers used EEG to track brain activity during sessions. They performed MRI scans and diffusion tensor imaging (DTI) to assess brain structure and connectivity before dosing and one month later. Participants also filled out assessments on insight, well-being, and cognitive flexibility at multiple points after each session.
Acute Effects of the High Dose
The 1 mg dose showed no notable effects across measures. In contrast, the 25 mg dose created profound impacts. Most participants called it the “single most unusual state of consciousness” they had ever known.
EEG readings revealed higher “brain entropy” during the high-dose experience. The Journal of Neuroscience Methods defines brain entropy as the “measure of the complexity of brain activity that has been linked to various cognitive abilities.” Such increases may help disrupt rigid, unhealthy thinking patterns.
Links to Psychological Improvements
Those with the largest rises in brain entropy reported greater psychological insight the day after dosing. At the four-week mark, they also showed better mental well-being. These outcomes point to sustained benefits from the psychedelic experience.
For tools to explore related research concepts, check the Peptide Glossary or latest peptide news.
Evidence of Structural Brain Changes
DTI scans detected alterations in white matter pathways one month post high dose. These pathways relate to decision-making and emotion. Researchers noted that confirmation in future work would mark the first observation of “anatomical ‘neuroplasticity’” from a psychedelic in humans.
The changes suggest more efficient brain connections. Such neuroplasticity could underlie long-term mental health gains. Learn more about stability in research compounds with the Stability Calculator.
Expert Views on Findings
Robin Carhart-Harris, PhD, a neurology professor at UCSF and senior study author, discussed well-being improvements with Medical News Today. “It will therefore be relevant to people with depression and anxiety who will typically be low in well-being,” said Carhart-Harris. “This study suggests psilocybin therapy can improve general mental health and suggests candidate brain and psychological mechanisms for how this happens.”
Zishan Khan, MD, a board-certified psychiatrist and Regional Medical Director with Mindpath Health, called the work “carefully conducted, but still early-stage.” He praised the multimodal approach but noted the small sample size makes results hypothesis-generating, not definitive. Khan stressed that brain shifts might indicate neuroplasticity, yet need longer-term validation.
Andrew Coop, PhD, professor and associate dean for students at the University of Maryland School of Pharmacy, highlighted ongoing Phase III trials for psilocybin. “Psilocybin has the potential to be a mainstream treatment,” he said. The study bolsters a new federal executive order to speed psychedelic research for mental illness access.
Broader Context and Limitations
Psilocybin occurs in “magic mushrooms” and shows promise for treatment-resistant depression. Controlled use remains legal in only three states. While brain flexibility increases and thought patterns shift, exact mechanisms require clarification.
Experts agree more studies are essential before routine clinical use. Khan stated the findings do not make psilocybin “ready for primetime” in psychiatry. Still, they build evidence combining neuronal effects with the psychedelic state.
In summary, this research connects a single psilocybin dose to persistent brain alterations and mental health gains. Replication in larger groups will clarify therapeutic potential. Use the Dosage & Cycle Planner for precise research planning.
